Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Grows By 206.2%

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 88,500 shares, a growth of 206.2% from the January 31st total of 28,900 shares. Based on an average trading volume of 153,300 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the company's stock are short sold.

enGene Price Performance

ENGN stock traded down $0.05 during mid-day trading on Tuesday, hitting $5.79. The stock had a trading volume of 16,596 shares, compared to its average volume of 124,962. The firm has a fifty day simple moving average of $6.74 and a 200 day simple moving average of $7.17. The firm has a market capitalization of $256.01 million, a P/E ratio of -9.98 and a beta of -0.65. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. As a group, research analysts forecast that enGene will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. HC Wainwright assumed coverage on enGene in a research report on Monday, December 23rd. They set a "buy" rating and a $25.00 price objective for the company. UBS Group downgraded shares of enGene from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $34.00 to $7.00 in a report on Friday, February 14th. Raymond James began coverage on shares of enGene in a report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 target price for the company. Citizens Jmp upgraded shares of enGene to a "strong-buy" rating in a research note on Monday, November 18th. Finally, JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.89.

Remove Ads

Hedge Funds Weigh In On enGene

Several large investors have recently bought and sold shares of the company. Wolverine Asset Management LLC acquired a new position in shares of enGene in the third quarter valued at approximately $37,000. Vontobel Holding Ltd. acquired a new position in enGene in the 4th quarter valued at approximately $69,000. Jane Street Group LLC bought a new position in shares of enGene during the fourth quarter valued at $93,000. Toronto Dominion Bank acquired a new position in shares of enGene during the fourth quarter worth $97,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.